Download PDFPDF

Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • A rapid response is a moderated but not peer reviewed online response to a published article in a BMJ journal; it will not receive a DOI and will not be indexed unless it is also republished as a Letter, Correspondence or as other content. Find out more about rapid responses.
  • We intend to post all responses which are approved by the Editor, within 14 days (BMJ Journals) or 24 hours (The BMJ), however timeframes cannot be guaranteed. Responses must comply with our requirements and should contribute substantially to the topic, but it is at our absolute discretion whether we publish a response, and we reserve the right to edit or remove responses before and after publication and also republish some or all in other BMJ publications, including third party local editions in other countries and languages
  • Our requirements are stated in our rapid response terms and conditions and must be read. These include ensuring that: i) you do not include any illustrative content including tables and graphs, ii) you do not include any information that includes specifics about any patients,iii) you do not include any original data, unless it has already been published in a peer reviewed journal and you have included a reference, iv) your response is lawful, not defamatory, original and accurate, v) you declare any competing interests, vi) you understand that your name and other personal details set out in our rapid response terms and conditions will be published with any responses we publish and vii) you understand that once a response is published, we may continue to publish your response and/or edit or remove it in the future.
  • By submitting this rapid response you are agreeing to our terms and conditions for rapid responses and understand that your personal data will be processed in accordance with those terms and our privacy notice.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Antiviral treatment initiation costs in chronic Hepatitis C
    • Uwe Siebert, Epidemiologist, Decision Scientist
    • Other Contributors:
      • Juergen Wasem, Siegbert Rossol, Gaby Sroczynski, Pamela Aidelsburger, Ulrike Ravens-Sieberer, Baerbel M Kurth, Michael P Manns, John G McHutchison, John B Wong

    Dear Editor

    We thank Dr Poynard for his comments highlighting the role of pretreatment evaluation costs prior to antiviral treatment of patients with chronic hepatitis C. The rate of fibrosis progression varies among individuals with chronic hepatitis C, so liver biopsy can identify those with advanced disease who are at greatest risk for progressing to decompensated cirrhosis when therapeutic options are limited...

    Show More
    Conflict of Interest:
    None declared.
  • Published on:
    Initiation of treatment costs

    Dear Editor

    I read with a great interest the excellent cost effectiveness analysis of pegylated interferon alpha 2b and ribavirin combination in patients with chronic hepatitis C.[1] I was surprised by the relatively low cost of treatment initiation in Germany (Table 3). The cost estimate of pretherapeutic diagnostics at 473 Euros inclu...

    Show More
    Conflict of Interest:
    None declared.